Clinical Trial: ECOG-ACRIN EA3231

ECOG-ACRIN EA3231

Status: New, Open

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Eligible for screening study DCP 001